Patient characteristics for the whole cohort
| Implants | 400 |
| Explantations | 96 |
| Explant reasons, No. (% of explantations) | |
| Diminished pain relief | 53 (55.2) |
| Conditions requiring MRI | 17 (17.7) |
| Infection | 8 (8.3) |
| Frequent dislocation | 1 (1.0) |
| IPG pocket pain | 2 (2.1) |
| No longer pain | 4 (4.2) |
| Other reason | 11 (11.5) |
| Age, years (mean±SD) | 51.8±12.5 |
| Gender, No. (%) | |
| Male | 165 (41.2) |
| Female | 235 (58.8) |
| Indication for implantation, No. (%) | |
| PSPS2 | 244 (61.0) |
| PSPS1 | 19 (4.8) |
| Peripheral neuralgia | 47 (11.8) |
| Intercostal neuralgia | 17 (4.3) |
| Polyneuropathy | 12 (3.0) |
| CRPS | 41 (10.3) |
| Other | 20 (5.0) |
| Follow-up time, months (median, IQR) | 47.5 (25-74) |
| Time to explantation, months (median, IQR) | 26 (14-45) |
| SCS system, No. (%) | |
| Boston Scientific | 148 (37.0) |
| Medtronic | 110 (27.5) |
| Nevro | 90 (22.5) |
| Abbott | 47 (11.8) |
| Saluda | 5 (1.3) |
| Rechargeable, No. (%) | |
| Yes | 272 (68.0) |
| No | 128 (32.0) |
| DRG stimulation, No. (%) | 16 (4.0) |
| Diabetes mellitus, No. (%) | |
| Yes | 27 (6.8) |
| No | 373 (93.2) |
| Immunosuppression treatment, No. (%) | |
| Yes | 11 (2.8) |
| No | 389 (97.2) |
CRPS, complex regional pain syndrome; DRG, dorsal root ganglion; IPG, implantable pulse generator; PSPS1, persistent spinal pain syndrome type 1; PSPS2, persistent spinal pain syndrome type 2; SCS, spinal cord stimulation.